All In Biotech

Drug Trial Radar · NCT00574249

Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment

A Multi-center, Randomized, Vehicle-Controlled Study to Assess the Efficacy and Safety of Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment (BELIEVE)

Last checked: Nov 19, 2026Latest source record: Apr 13, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 730 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

730

Actual

Start

Nov 2007

Primary completion

Oct 2008

Sponsor

Lead sponsor
AbbottIndustry
Sponsor type
Industry
First posted
Dec 17, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the efficacy and safety of adalimumab in combination with topical psoriasis treatment, calcipotriol/betamethasone, vs. adalimumab in combination with matching vehicle in subjects with moderate to severe chronic plaque psoriasis.

Conditions

  • Chronic Plaque Psoriasis

Interventions

  • adalimumabBiological

    subcutaneous injection using prefilled pen/syringe, solution containing 40 mg in 0.8 milliliters; 2 injections given at Baseline (Day 1) then once every other week from Weeks 1 though 15

  • Calcipotriol/Betamethasone OintmentDrug

    Topical ointment (calcipotriol 50 mcg/g and betamethasone 500 mcg/g) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16

  • placebo (vehicle ointment)Drug

    Topical vehicle ointment (matching active calcipotriol/betamethasone ointment) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieve a PASI75 Response at Week 16 Compared With Baseline (Week 0)Time frame: Week 0 and Week 16

Locations

131 sites in 15 countries. Site status is shown where the registry gives one.

  • Site not named

    Graz, Austria

  • Site not named

    Innsbruck, Austria

  • Site not named

    Salzburg, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Wein, Austria

  • Site not named

    Aalst, Belgium

  • Site not named

    Bruges, Belgium

  • Site not named

    Brussels, Belgium

  • Site not named

    Brussels, Belgium

  • Site not named

    Brussels, Belgium

  • Site not named

    Edegem, Belgium

  • Site not named

    Geel, Belgium

  • Site not named

    Ghent, Belgium

  • Site not named

    Kortrijk, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Liège, Belgium

  • Site not named

    Mons, Belgium

  • Site not named

    Brno, Czechia

  • Site not named

    Hradec Králové, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Arhus C, Denmark

  • Site not named

    Copenhagen, Denmark

  • Site not named

    Hellerup, Denmark

  • Site not named

    Herning, Denmark

  • Site not named

    Helsinki HUS, Finland

  • Site not named

    Jyväskylä, Finland

  • Site not named

    Lahti, Finland

  • Site not named

    Brest, France

  • Site not named

    Créteil, France

  • Site not named

    Lille, France

  • Site not named

    Limoges, France

  • Site not named

    Montpellier, France

  • Site not named

    Nancy, France

  • Site not named

    Nice, France

  • Site not named

    Paris, France

  • Site not named

    Pessac, France

  • Site not named

    Pierre-Bénite, France

  • Site not named

    Rouen, France

  • Site not named

    Saint-Etienne, France

Showing 40 of 131 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.